- Zacks Small Cap Research•15 days ago
Medgenics (MDGN) reported financial results for the second quarter ending June 30th and provided and operational update including status reports on their NFC-1 programs in ADHD and 22q Deletion Syndrome as well as their anti-LIGHT candidate targeting severe pediatric onset IBD. Q2 net loss and EPS were $11.7M and ($0.35), compared to our $11.4M and ($0.35) estimates. Cash used in operating activities was $9.8M and $18.9M in the first three and six months of 2016. Cash balance, bolstered by the June equity raise (3.8M shares @ $5.50/share) which netted ~$19.7M, was $53.7M at quarter end. The sizeable raise and beefed-up cash balance allows development programs to remain on track and at their accelerated pace. Management expects current cash to fund operations through Q1 2018. By that time NFC-1 should have significant data points in both mGlurR+ ADHD and 22q and initial responder data should be available from the anti-LIGHT program.
- Associated Press•21 days ago
On a per-share basis, the Wayne, Pennsylvania-based company said it had a loss of 35 cents. Medgenics shares have fallen slightly since the beginning of the year. The stock has dropped 23 percent in the ...
Medgenics, Inc. (MDGN)
NYSE MKT - NYSE MKT Delayed Price. Currency in USD
|Bid||5.75 x 400|
|Ask||13.02 x 500|
|Day's Range||5.68 - 5.87|
|52wk Range||3.09 - 10.25|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-3.89|
|Avg Vol (3m)||145,515|
|Dividend & Yield||N/A (N/A)|